Equidacent

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Shusha Taarifa za kipeperushi (PIL)
25-11-2021
Shusha Tabia za bidhaa (SPC)
25-11-2021

Viambatanisho vya kazi:

bevacizumab

Inapatikana kutoka:

Centus Biotherapeutics Europe Limited

ATC kanuni:

L01XC07

INN (Jina la Kimataifa):

bevacizumab

Kundi la matibabu:

Antineoplastic agents

Eneo la matibabu:

Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell

Matibabu dalili:

Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Equidacent in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.Bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Bidhaa muhtasari:

Revision: 3

Idhini hali ya:

Withdrawn

Idhini ya tarehe:

2020-09-24

Taarifa za kipeperushi

                                60
B.
PACKAGE LEAFLET
Medicinal product no longer authorised
61
PACKAGE LEAFLET: INFORMATION FOR THE USER
EQUIDACENT 25 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION
bevacizumab
This medicine is subject to additional monitoring. This will allow
quick identification of new
safety information. You can help by reporting any side effects you may
get. See the end of section 4
for how to report side effects.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor, pharmacist or
nurse.

If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Equidacent is and what it is used for
2.
What you need to know before you use Equidacent
3.
How to use Equidacent
4.
Possible side effects
5.
How to store Equidacent
6.
Contents of the pack and other information
1.
WHAT EQUIDACENT IS AND WHAT IT IS USED FOR
Equidacent contains the active substance bevacizumab, which is a
humanised monoclonal antibody (a
type of protein that is normally made by the immune system to help
defend the body from infection
and cancer).

Bevacizumab binds selectively to a protein called human vascular
endothelial growth factor
(VEGF), which is found on the lining of blood and lymph vessels in the
body.

The VEGF protein causes blood vessels to grow within tumours, these
blood vessels provide the
tumour with nutrients and oxygen.

Once bevacizumab is bound to VEGF, tumour growth is prevented by
blocking the growth of the
blood vessels which provide the nutrients and oxygen to the tumour.
ADVANCED CANCER IN THE LARGE BOWEL
Equidacent is a medicine used for the treatment of adult patients with
advanced cancer in the large
bowel, i.e., in the colon or rectum. Equidacent will be administered
in combination with chemotherapy
treatment 
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
This medicinal product is subject to additional monitoring. This will
allow quick identification of
new safety information. Healthcare professionals are asked to report
any suspected adverse reactions.
See section 4.8 for how to report adverse reactions.
1.
NAME OF THE MEDICINAL PRODUCT
Equidacent 25 mg/mL concentrate for solution for infusion.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each mL of concentrate contains 25 mg of bevacizumab*.
Each vial of 4 mL of concentrate contains 100 mg of bevacizumab.
Each vial of 16 mL of concentrate contains 400 mg of bevacizumab.
For dilution and other handling recommendations, see section 6.6.
*Bevacizumab is a recombinant humanised monoclonal antibody produced
by DNA technology in
Chinese Hamster Ovary cells.
Excipient(s) with known effect
Each vial of 4 mL of concentrate contains 191 mg sorbitol (E420).
Each vial of 16 mL of concentrate contains 764 mg sorbitol (E420).
For the full list of excipients see section 6.1.
3.
PHARMACEUTICAL FORM
Concentrate for solution for infusion.
Clear to opalescent, colourless to pale brownish-yellowish solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Bevacizumab in combination with fluoropyrimidine-based chemotherapy is
indicated for treatment of
adult patients with metastatic carcinoma of the colon or rectum.
Bevacizumab in combination with paclitaxel is indicated for first-line
treatment of adult patients with
metastatic breast cancer. For further information as to human
epidermal growth factor receptor 2
(HER2) status, please refer to section 5.1.
Bevacizumab in combination with capecitabine is indicated for
first-line treatment of adult patients
with metastatic breast cancer in whom treatment with other
chemotherapy options including taxanes
or anthracyclines is not considered appropriate. Patients who have
received taxane and anthracycline-
containing regimens in the adjuvant setting within the last 12 months
should be excluded from
t
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kibulgaria 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kihispania 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kicheki 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kidenmaki 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kijerumani 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kiestonia 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kigiriki 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kifaransa 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kiitaliano 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kilatvia 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kilithuania 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kihungari 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kimalta 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kiholanzi 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kipolandi 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kireno 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kiromania 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kislovakia 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kislovenia 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kifinlandi 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kiswidi 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kinorwe 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 25-11-2021
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 25-11-2021
Tabia za bidhaa Tabia za bidhaa Kroeshia 25-11-2021
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 25-11-2021

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati